GSK and Astrazeneca shares slump as Trump vows drug price cut May 12, 2025 GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.
FTSE 100’s record run ends as pharma stocks slide on new Trump appointment May 7, 2025 The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment. The blue-chip index spent the entire session in the red and closed off 0.4 per cent. Drugmakers GSK and Astrazeneca were among the top fallers, at nearly five per cent and [...]
GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs April 30, 2025 British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]
As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? April 22, 2025 For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks. The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]
Starmer must act now to protect NHS from Trump pharma tariffs April 17, 2025 Starmer must make a deal to avoid Trump's pharma tariffs or risk a major hit to the NHS, write Ben Ramanauskas and Sean Phillips.
Government scrambles to swerve Trump pharma tariffs April 16, 2025 A race against time is underway to shield the UK pharmaceutical sector from potentially swinging Trump tariffs on imported drugs. As it stands, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming into the US. However, President Trump has warned that there will be tariffs on imported pharma [...]
Hikma’s profit jumps as demand for generic medicines booms February 26, 2025 Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable to shareholders nearly doubled, reaching $359m (£284m), while earnings per share rose 88 per cent. The multinational pharmaceutical company that develops, manufactures, and markets a [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
FTSE 100 giant GSK eyes more than £40bn in sales by 2031 February 5, 2025 Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]
Support for innovation is needed in Budget warns pharmaceutical industry October 15, 2024 The Association of the British Pharmaceutical Industry (ABPI) has called on Rachel Reeves to prioritise research and development (R&D) investment in the coming Labour Budget to unlock the potential of the UK life sciences sector. The APBI’s pre-Budget submission stressed the importance of maintaining and increasing public R&D funding to increase the UK’s attractiveness as [...]